Monday 1 July 2024

The Pharma Letter Podcast — Episode 26 — CRO sector surges in bio revolution

Biotechnology
Simon Wentworth
24 October 2023
episode26-large-podcast

More on this story...

Pharmaceutical
Two new hires at Asia-Pacific-focused CRO Novotech
13 October 2023
Biotechnology
Singaporean CRO Novotech appoints new chief medical officer
4 October 2023
Pharmaceutical
Growing CDMO appoints new president of Novasep business
19 October 2023
Pharmaceutical
Data show outsourcing growth set to continue in future
1 December 2023


Related Company News

Morningstar research shows growing role for CROs and CDMOs
Data show outsourcing growth set to continue in future
New clinical trial partnership to help LEO Pharma move at pace
BIA gains approval to intervene in patent dispute
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze